Annals of medicine and surgery (2012) · 2025
Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ashraf Taimoor, Kumar Akshy, Tara Aniket, Memon Naila, Muhammad Areej, Turesh Muskan, Dev Shah, Muhammad Noor, Kumar Vikash, Hussain Tooba, Kumar Ravesh, Singh Ajeet, Bajaj Simran, Qammar Asfia, Deepak Fnu, Kumar Aadesh, Yusuf Salih Abdella
Аннотация
INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a progressive condition often necessitating insulin therapy for sustained glycemic control, yet adherence to daily injections remains a significant challenge. While insulin glargine is effective, reducing injection frequency may improve compliance and outcomes. This study evaluates the efficacy and safety of once-weekly insulin icodec compared to once-daily insulin glargine U100.
METHODS: This systematic review and meta-analysis followed Cochrane and PRISMA guidelines. A comprehensive search across multiple databases identified randomized controlled trials (RCTs) comparing once-weekly insulin icodec with once-daily insulin glargine U100 in adults with T2DM. Eligible studies included adult participants and reported glycemic or safety outcomes. Data synthesis was performed using a random-effects model, with heterogeneity assessed via the I2 statistic.
RESULTS: Five RCTs comprising 2,019 participants met the inclusion criteria. Insulin icodec significantly reduced glycated hemoglobin (MD: -0.12; 95% CI: -0.20, -0.04; P = 0.003) and increased time in range (TIR; MD: 4.23; 95% CI: 2.20, 6.26; P < 0.0001) compared to insulin glargine. A modest increase in body weight was observed with insulin icodec, while safety profiles, including hypoglycemia rates and adverse events, were comparable between treatments.
CONCLUSION: Insulin icodec provides a safe and effective alternative to once-daily insulin glargine for T2DM management, offering similar glycemic control with a once-weekly dosing regimen. The reduced injection burden may enhance adherence and treatment satisfaction, potentially improving long-term disease outcomes.
METHODS: This systematic review and meta-analysis followed Cochrane and PRISMA guidelines. A comprehensive search across multiple databases identified randomized controlled trials (RCTs) comparing once-weekly insulin icodec with once-daily insulin glargine U100 in adults with T2DM. Eligible studies included adult participants and reported glycemic or safety outcomes. Data synthesis was performed using a random-effects model, with heterogeneity assessed via the I2 statistic.
RESULTS: Five RCTs comprising 2,019 participants met the inclusion criteria. Insulin icodec significantly reduced glycated hemoglobin (MD: -0.12; 95% CI: -0.20, -0.04; P = 0.003) and increased time in range (TIR; MD: 4.23; 95% CI: 2.20, 6.26; P < 0.0001) compared to insulin glargine. A modest increase in body weight was observed with insulin icodec, while safety profiles, including hypoglycemia rates and adverse events, were comparable between treatments.
CONCLUSION: Insulin icodec provides a safe and effective alternative to once-daily insulin glargine for T2DM management, offering similar glycemic control with a once-weekly dosing regimen. The reduced injection burden may enhance adherence and treatment satisfaction, potentially improving long-term disease outcomes.